N4F. PILOT PROJECTS We typically aim to provide catalytic funding for two Pilot projects during each grant year. Pilot projects are funded for a period of two years at a level in the range of ~$6oK-9oK direct costs per year. The level depends on the extent of personnel and materials/supplies requirement for gaining preliminary results, and the time period permits assessment of how well the science and investigators integrate into the ongoing Projects or Core. The Pilot projects are selected by the Steering Committee from applications submitted by investigators in the MIT (and Harvard) communities, on the basis of potential for providing powerful new approaches that complement overall program aims. If deemed highly successful in collaborative integration, the Pilot investigator(s) can become regular PIs in the Projects or Core. During the previous grant period, Pilots directed by Ernest Fraenkel and Mike Hemann have done so, with results described in the Progress Report section and plans described in the Research Plans section for their corresponding Project and Core participation. The two Pilots intended for Year 6 of the grant if successfully renewed are presented below.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA112967-08
Application #
8375834
Study Section
Special Emphasis Panel (ZCA1-SRLB-C)
Project Start
2012-04-17
Project End
2015-02-28
Budget Start
2012-04-17
Budget End
2013-02-28
Support Year
8
Fiscal Year
2012
Total Cost
$122,362
Indirect Cost
Name
Massachusetts Institute of Technology
Department
Type
DUNS #
001425594
City
Cambridge
State
MA
Country
United States
Zip Code
02139
Lescarbeau, Rebecca S; Lei, Liang; Bakken, Katrina K et al. (2016) Quantitative Phosphoproteomics Reveals Wee1 Kinase as a Therapeutic Target in a Model of Proneural Glioblastoma. Mol Cancer Ther 15:1332-43
Oudin, Madeleine J; Miller, Miles A; Klazen, Joelle A Z et al. (2016) MenaINV mediates synergistic cross-talk between signaling pathways driving chemotaxis and haptotaxis. Mol Biol Cell 27:3085-3094
Tape, Christopher J; Ling, Stephanie; Dimitriadi, Maria et al. (2016) Oncogenic KRAS Regulates Tumor Cell Signaling via Stromal Reciprocation. Cell 165:910-20
Lescarbeau, Rebecca S; Lei, Liang; Bakken, Katrina K et al. (2016) Quantitative phosphoproteomics reveals Wee1 kinase as a therapeutic target in a model of proneural glioblastoma. Mol Cancer Ther :
de Picciotto, Seymour; Dickson, Paige M; Traxlmayr, Michael W et al. (2016) Design Principles for SuCESsFul Biosensors: Specific Fluorophore/Analyte Binding and Minimization of Fluorophore/Scaffold Interactions. J Mol Biol 428:4228-4241
Miller, Miles A; Oudin, Madeleine J; Sullivan, Ryan J et al. (2016) Reduced Proteolytic Shedding of Receptor Tyrosine Kinases Is a Post-Translational Mechanism of Kinase Inhibitor Resistance. Cancer Discov 6:382-99
Tuncbag, Nurcan; Gosline, Sara J C; Kedaigle, Amanda et al. (2016) Network-Based Interpretation of Diverse High-Throughput Datasets through the Omics Integrator Software Package. PLoS Comput Biol 12:e1004879
Carmona, G; Perera, U; Gillett, C et al. (2016) Lamellipodin promotes invasive 3D cancer cell migration via regulated interactions with Ena/VASP and SCAR/WAVE. Oncogene 35:5155-69
Reddy, Raven J; Gajadhar, Aaron S; Swenson, Eric J et al. (2016) Early signaling dynamics of the epidermal growth factor receptor. Proc Natl Acad Sci U S A 113:3114-9
Oudin, Madeleine J; Jonas, Oliver; Kosciuk, Tatsiana et al. (2016) Tumor Cell-Driven Extracellular Matrix Remodeling Drives Haptotaxis during Metastatic Progression. Cancer Discov 6:516-31

Showing the most recent 10 out of 206 publications